Fujirebio's transition from oncology to neurodegenerative diseases was not built from scratch. It was accelerated by acquiring Innogenetics, a Belgian company that had already spent two decades researching Alzheimer's biomarkers. This "buy vs. build" strategy enabled a rapid and expert entry into a new therapeutic area.

InflaRx's strategy targets the C5a pathway, implicated in many inflammatory conditions. By focusing on this single mechanism, their drug could potentially treat a wide range of diseases, from skin conditions to kidney disease, effectively creating a valuable "pipeline in a drug."

In its Phase 2 trial, Acadia isn't using biomarkers to discover new insights but to confirm patients have the biological underpinnings of Alzheimer's disease. This marks a significant shift, demonstrating that biomarkers have matured into a standard diagnostic component for ensuring a homogenous and accurately defined patient population in clinical research.

Bio Arctic is applying its successful Alzheimer's playbook to Parkinson's disease. This involves a highly selective compound that targets only the toxic protein aggregates (alpha-synuclein) while sparing healthy forms, combined with ensuring patients with the correct pathology are selected for trials.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.

BioAge is framing its oral drug BGE-102 as a single asset that can address inflammation across cardiovascular, ocular, and CNS diseases. This "pipeline in a pill" strategy transforms a single molecule into a broad platform by targeting a fundamental aging mechanism that cuts across many tissues and conditions.

The blood test is a first-line screen to identify patients who may need more invasive and expensive follow-ups like PET scans or CSF tests. This minimizes unnecessary procedures for those at low risk, optimizing the diagnostic pathway and improving patient experience.

Avenco is strategically targeting Traumatic Brain Injury (TBI) alongside Alzheimer's. The rationale is that TBI presents the same pathological changes—inflammation and plaque formation—but on a much faster timeline. This makes it a compelling, and currently untreated, market for their neuroinflammation-targeting therapy, de-risking their platform beyond a single disease.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.